Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed a sufficient level of participation to move forward with its nationwide settlement agreement to resolve opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States. Teva has either already settled with or confirmed participation from 48 of the 50 states and will continue to pursue participation by those states that have yet to join. The sign-on process for the states’ subdivisions will now begin. Given the very positive response from states, the Company remains optimistic that the nationwide settlement will garner similar support from the states’ subdivisions.
As previously announced, Teva has reached an agreement with the working group of States’ Attorneys General and plaintiffs’ lawyers representing the states and subdivisions, on the nationwide opioids settlement. While the agreement will include no admission of wrongdoing, it remains in the Company’s best interest – and in the interest of those impacted by the opioid crisis – to settle these cases and to continue to focus on the patients Teva serves every day.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
Last Trade: | US$17.96 |
Daily Change: | -0.19 -1.05 |
Daily Volume: | 2,439,471 |
Market Cap: | US$20.290B |
October 08, 2024 October 03, 2024 September 23, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB